Clinical trial Recruiting at 1 site Phase 4 Interventional Ages 40 to 60

Nalbuphine versus fentanyl to reduce blood pressure and heart rate changes during laryngoscopy and intubation

Official title: COMPARISON OF HEMODYNAMIC EFFECTS OF NALBUPHINE VERSUS FENTANYL: A RANDOMIZED, DOUBLE-BLINDED INTERVENTIONAL STUDY IN PATIENTS ON CARDIOPULMONARY BYPASS AT RAWALPINDI INSTITUTE OF CARDIOLOGY, RAWALPINDI

Run by Rawalpindi Institute of Cardiology · NCT07435337 · Data updated 2026-11-12

This test sees if nalbuphine or fentanyl better prevents spikes in heart rate and blood pressure during intubation for people having cardiac surgery.

More Hemodynamic Changes trials

Quick facts

PhasePhase 4
Study typeInterventional
Ages40 Years to 60 Years
SexAll
Enrollment98 (estimated)
SponsorRawalpindi Institute of Cardiology
Academic / other
Locations1 site (Rawalpindi, Punjab Province)
StatusRecruiting
StartedFebruary 21, 2026
Main results expectedMay 21, 2026
Study endsMay 21, 2026
Registry record updatedFebruary 27, 2026
Trial IDNCT07435337 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adults ASA III weighing 40–70 kg who are scheduled for cardiac surgery with cardiopulmonary bypass and meet the trial's inclusion and exclusion criteria.

Probably not a fit

Patients with pre-existing asthma, significant renal or hepatic dysfunction, extreme obesity, pregnancy or lactation, or anticipated difficult intubation are excluded and would not be expected to benefit from this protocol.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Adults scheduled for cardiac surgery will receive standard premedication and invasive monitoring including central venous and arterial lines, then be given either nalbuphine (0.2 mg/kg) or fentanyl (3 µg/kg) intravenously before induction with etomidate and muscle relaxation with atracurium. Endotracheal intubation will be performed under direct laryngoscopy and hemodynamic parameters (heart rate and arterial blood pressure) will be recorded continuously around the time of laryngoscopy and during the intraoperative period. Anesthesia will be maintained with sevoflurane and a continuous atracurium infusion while measurements are compared between the two opioid groups to determine which drug better blunts the laryngoscopic stress response. Standard exclusion criteria include asthma, significant renal or hepatic dysfunction, extreme obesity, pregnancy or lactation, and anticipated difficult or prolonged intubation.

Why it matters

Potential benefit: If successful, the preferred opioid could reduce dangerous blood pressure and heart rate spikes during intubation, improving hemodynamic stability and potentially lowering perioperative complications.

How similar studies have gone: Fentanyl and other opioids are well established to blunt laryngoscopy-induced hemodynamic responses, while nalbuphine has been less widely studied but some smaller trials suggest similar effects.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Weighing 40-70kg

  * ASA III of either sex
  * Undergoing cardiac surgery with CPB

Exclusion Criteria:

• History of Drug Allergy • Pre-existing Asthma • Renal or Hepatic dysfunction • Extreme obesity • Pregnant / lactating patients • Difficult intubation/prolonged intubation

Where it's running

  • Deparment of Anesthesia, Rawalpindi Institute of Cardiology, Rawalpindi
    Rawalpindi, Punjab Province, Pakistan
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.